1 active not recruiting, 1 withdrawn. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Withdrawn 1 |
Follow CB-010: new trials by email Literature Review of CB-010 trials Research Report on CB-010
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) CB-010 - Systemic Lupus Erythematosus, Lupus | Phase 1 | Withdrawn | Caribou Biosciences, Inc. | 2027-12-01 | 2025-09-19 | |
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) CB-010, Cyclophosphamide, Fludarabine - Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma | Phase 1 | Active not recruiting | Caribou Biosciences, Inc. | 72 | 2021-05-26 | 2026-10-19 |
Autoimmune Diseases (1) · Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1)
Australia (1) · Israel (1) · United States (1)